Evidence map›Paper›PMID 41113053›Full record

ArticleAmerican journal of translational research2025

Study on drug sensitivity and clinical application of tumor organoid-based colorectal cancer models.

Yiwang Hu, Junchang Zhu, Yinjie Zheng, Jinyuan Zhang, Kai Yang, Yifei Pan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yiwang HuDepartment of Colorectal and Anal Surgery, The First Affiliated Hospital of Wenzhou Medical University, Nanbaixiang Campus Wenzhou 325000, Zhejiang, China.
Junchang ZhuDepartment of Colorectal and Anal Surgery, The First Affiliated Hospital of Wenzhou Medical University, Nanbaixiang Campus Wenzhou 325000, Zhejiang, China.
Yinjie ZhengDepartment of Colorectal and Anal Surgery, The First Affiliated Hospital of Wenzhou Medical University, Nanbaixiang Campus Wenzhou 325000, Zhejiang, China.
Jinyuan ZhangDepartment of Colorectal and Anal Surgery, The First Affiliated Hospital of Wenzhou Medical University, Nanbaixiang Campus Wenzhou 325000, Zhejiang, China.
Kai YangDepartment of Colorectal and Anal Surgery, The First Affiliated Hospital of Wenzhou Medical University, Nanbaixiang Campus Wenzhou 325000, Zhejiang, China.
Yifei PanDepartment of Colorectal and Anal Surgery, The First Affiliated Hospital of Wenzhou Medical University, Nanbaixiang Campus Wenzhou 325000, Zhejiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo establish and validate a patient-derived organoid (PDO) model of colorectal cancer (CRC) for drug sensitivity testing and assess its correlation with clinical treatment outcomes.

methodsTumor tissues were collected from 16 CRC patients undergoing surgery. PDOs were successfully generated from 9 cases and exposed to five chemotherapeutic agents (5-FU, oxaliplatin, irinotecan, raltitrexed, trifluridine) and one targeted therapy (cetuximab). IC50 values (half-maximal inhibitory concentration) and inhibition rates were determined and compared with patients' clinical responses.

resultsPDOs displayed heterogeneity in drug sensitivity. RAS-mutant organoids were consistently resistant to cetuximab, whereas RAS wild-type organoids showed variable responses. In most cases, PDO drug responses correlated with clinical treatment outcomes, suggesting that the PDO model can accurately reflect individual therapeutic sensitivity.

conclusionsCRC PDOs can be efficiently established and serve as reliable in vitro models for predicting responses to chemotherapy and targeted therapies. This approach may guide personalized treatment strategies and improve clinical decision-making in CRC.

Indexed as

cetuximabColorectal cancerdrug sensitivityorganoidsprecision medicineRAS mutation

Identifiers

PMID41113053
PMCPMC12531565

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.